The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FAF, ICPT and LRN
Back to Newsroom
Mentioned in this Article

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FAF, ICPT and LRN

Friday, December 18, 2020 4:55 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / December 18, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

First American Financial Corp. (NYSE:FAF)
Class Period: February 17, 2017 - October 22, 2020
Lead Plaintiff Deadline: December 24, 2020

During the class period, First American Financial Corp. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company failed to implement basic security standards to protect its customers' sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in FAF: http://www.kleinstocklaw.com/pslra-1/first-american-financial-corp-loss-submission-form?id=11695&from=1

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
Class Period: September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline: January 4, 2021

The complaint alleges that during the class period Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ICPT: http://www.kleinstocklaw.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?id=11695&from=1

K12 Inc. (NYSE:LRN)
Class Period: April 27, 2020 - September 18, 2020
Lead Plaintiff Deadline: January 19, 2021

The complaint alleges that throughout the class period K12 Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) K12 lacked the technological capabilities, infrastructures, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (ii) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer system; (iii) K12 was unable provide the necessary levels of administrative support and training to teachers, students, and parents; and (iv) based on the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's business, operations, and prospects and/or lacked a reasonable basis and omitted facts.

Learn about your recoverable losses in LRN: http://www.kleinstocklaw.com/pslra-1/k12inc-loss-submission-form?id=11695&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

The Klein Law Firm
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: